首页> 外文OA文献 >Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation : 2-year results of the C-OPERA study, a phase III randomised trial

【2h】

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation : 2-year results of the C-OPERA study, a phase III randomised trial

机译：停用类风湿关节炎后，观察到1年的certolizumab聚乙二醇（CZP）联合疗法与甲氨蝶呤治疗对早期类风湿关节炎的临床益处：C-OPERA研究的2年结果，一项III期随机试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Atsumi, Tatsuya; Tanaka, Yoshiya; Yamamoto, Kazuhiko; Takeuchi, Tsutomu; Yamanaka, Hisashi; Ishiguro, Naoki; Eguchi, Katsumi; Watanabe, Akira; Origasa, Hideki; Yasuda, Shinsuke; Yamanishi, Yuji; Kita, Yasuhiko; Matsubara, Tsukasa; Iwamoto, Masahiro; Shoji, Toshiharu; Togo, Osamu; Okada, Toshiyuki; van der Heijde, Désirée; Miyasaka, Nobuyuki; Koike, Takao;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial [J] . Atsumi Tatsuya, Tanaka Yoshiya, Yamamoto Kazuhiko, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2017,第8期

机译：在CZP停止后观察到甲氨酸中甲氨醇（CZP）加入治疗的临床益处（CZP）对甲氨蝶呤治疗的甲氨蝶呤治疗：C-Opera研究的2年结果，III期随机试验
2. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study [J] . Piercarlo Sarzi-Puttini, Emilio Filippucci, Silvano Adami, Advances in therapy. . 2018,第8期

机译：在中度至重度类风湿性关节炎患者中临床，超声波和可预测性结果（用甲氨蝶呤）：CZP速度研究的52周结果
3. The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life [J] . Roy Fleischmann Open access Rheumatology: Research and Reviews . 2009,第2期

机译：塞妥珠单抗（CZP）治疗类风湿关节炎的临床疗效和安全性：长期使用，患者注意事项以及对生活质量的影响
4. Extended report: Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study a phase III randomised trial [O] . Tatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto, -1

机译：扩展报告：停用类风湿关节炎后在甲氨蝶呤治疗中加入1年的certolizumab聚乙二醇（CZP）联合疗法对甲氨蝶呤治疗的临床益处：C-OPERA研究的2年结果一项III期随机试验
5. Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study [O] . Piercarlo Sarzi-Puttini, Emilio Filippucci, Silvano Adami, 2018

机译：临床，超声波和可预测性结果在中度至重度类风湿性关节炎的患者中进行了睾丸PEGOL治疗（用甲氨蝶呤）：CZP速度研究的52周结果

Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation : 2-year results of the C-OPERA study, a phase III randomised trial

著录项

相似文献

相关主题

期刊订阅